It's Time For a Quick Look at DENTSPLY SIRONA's Fundamentals.

DENTSPLY SIRONA marked a 2.9% change today, compared to 0.6% for the S&P 500. Is it a good value at today's price of $34.28? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide.

  • SIRONA belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07

  • The company's P/B ratio is 1.5

  • SIRONA has a trailing 12 month Price to Earnings (P/E) ratio of -90.2 based on its trailing 12 month price to earnings (EPS) of $-0.38 per share

  • Its forward P/E ratio is 11.1, based on its forward earnings per share (EPS) of $3.09

  • XRAY has a Price to Earnings Growth (PEG) ratio of 3.29, which shows the company is overvalued when we factor growth into the price to earnings calculus.

  • Over the last four years, SIRONA has averaged free cash flows of $524,300,000.00, which on average grew 0.7%

  • XRAY's gross profit margins have averaged 53.0 % over the last four years and during this time they had a growth rate of 2.1 % and a coefficient of variability of 5.8 %.

  • XRAY has an average analyst rating of hold and is -17.0% away from its mean target price of $41.3 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS